SterisCare's dual-action antidiabetic formulation Glimocare M2 (Glimepiride 2mg + Metformin HCl 500mg ER) has crossed 50,000 prescriptions within 18 months of commercial launch — a milestone that validates strong physician confidence in the formulation.
The milestone, independently verified through our prescription audit data provider, places Glimocare M2 among the fastest-growing new entrants in the glimepiride-metformin fixed-dose combination segment in India.
Physician Feedback Themes
- Consistent gastric tolerability vs. immediate-release metformin combinations.
- Once-daily dosing convenience supporting patient adherence.
- Reliable bioavailability attributed to our extended-release matrix technology.
We thank the endocrinologists, diabetologists, and general physicians who have placed their trust in Glimocare M2 and in SterisCare's commitment to quality-first manufacturing.
Keywords
